Abstract:Hospital-acquired infections caused by drug-resistant bacteria are a significant challenge to patient safety. Numerous clinical isolates resistant to almost all commercially available antibiotics have emerged. Thus, novel antimicrobial agents, specifically those for multidrug-resistant Gram-negative bacteria, are urgently needed. In the current study, we report the isolation, structure elucidation, and preliminary biological characterization of a new cationic lipopeptide antibiotic, battacin or octapeptin B5, produced from a Paenibacillus tianmuensis soil isolate. Battacin kills bacteria in vitro and has potent activity against Gram-negative bacteria, including multidrug-resistant and extremely drug-resistant clinical isolates. Hospital strains of Escherichia coli and Pseudomonas aeruginosa are the pathogens most sensitive to battacin, with MICs of 2 to 4 μg/ml. The ability of battacin to disrupt the outer membrane of Gram-negative bacteria is comparable to that of polymyxin B, the last-line therapy for infections caused by antibiotic-resistant Gram-negative bacteria. However, the capacity of battacin to permeate bacterial plasma membranes is less extensive than that of polymyxin B. The bactericidal kinetics of battacin correlate with the depolarization of the cell membrane, suggesting that battacin kills bacteria by disrupting the cytoplasmic membrane. Other studies indicate that battacin is less acutely toxic than polymyxin B and has potent in vivo biological activity against E. coli. Based on the findings of the current study, battacin may be considered a potential therapeutic agent for the treatment of infections caused by antibiotic-resistant Gram-negative bacteria.

A new class of antibiotics acts as molecular glue

A new antibiotic traps lipopolysaccharide in its intermembrane transporter

A novel antibiotic class targeting the lipopolysaccharide transporter

A new antibiotic selectively kills Gram-negative pathogens

A new type of antibiotic targets a drug-resistant bacterium

New class of antibiotics is a welcome discovery

Rational design of a new antibiotic class for drug-resistant infections

Battacin (octapeptin B5), A New Cyclic Lipopeptide Antibiotic from Paenibacillus Tianmuensis Active Against Multidrug-Resistant Gram-Negative Bacteria

Breaking down the cell wall: Still an attractive antibacterial strategy

A synthetic antibiotic overcomes antimicrobial resistance

Inhibitors targeting BamA in gram-negative bacteria

Lipopeptides from Bacillus and Paenibacillus spp.: A Gold Mine of Antibiotic Candidates

A new antibiotic from an uncultured bacterium binds to an immutable target

Caging Pyrophosphate Structure Blocks the Cell Wall Synthesis to Kill Bacteria Without Detectable Resistance

Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens

A Macromolecule Reversing Antibiotic Resistance Phenotype and Repurposing Drugs as Potent Antibiotics

Resurrecting ancestral antibiotics: unveiling the origins of modern lipid II targeting glycopeptides

Structural Insights into the Lipopolysaccharide Transport (Lpt) System as a Novel Antibiotic Target

Membrane-active macromolecules kill antibiotic-tolerant bacteria and potentiate antibiotics towards Gram-negative bacteria

An antibiotic from an uncultured bacterium binds to an immutable target

New β-lactam - Tetramic acid hybrids show promising antibacterial activities